Avenue Therapeutics Q1 EPS $(15.40) Misses $(9.00) Estimate
Portfolio Pulse from Benzinga Newsdesk
Avenue Therapeutics (NASDAQ:ATXI) reported a Q1 EPS of $(15.40), significantly missing the analyst consensus estimate of $(9.00) by 71.11%. This represents an 85.01% improvement over the $(102.75) per share loss from the same period last year.
May 15, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avenue Therapeutics reported a Q1 EPS of $(15.40), missing the analyst estimate of $(9.00) by 71.11%. Despite the miss, the loss is an 85.01% improvement from the same period last year.
The significant miss on the EPS estimate is likely to negatively impact the stock price in the short term. However, the improvement from last year's loss may provide some cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100